Table 2.

Quantitative magnetic resonance parameters. (A) Volumetric and functional assessment. (B) Myocardial tissue differentiation parameters.

				48 h after first dose		After therapy
			Before therapy		P value		P value
A
Non‐aCMP	LVEDV	mL	165.1 ± 39.6	177.5 ± 36.2	0.03	164.7 ± 34.8	0.67
	LVEF	%	59.2 ± 10.2	63.9 ± 7.9	0.02	58.3 ± 7.8	0.47
	RVEDV	mL	185.7 ± 41.8	196.0 ± 43.0	0.06	184.6 ± 40.7	0.52
	RVEF	%	47.3 ± 5.9	51.1 ± 6.2	<0.01	47.2 ± 5.8	0.98
	LVM	g	81.8 ± 21.0	81.8 ± 20.1	0.92	79.2 ± 18.1	0.33
aCMP	LVEDV	mL	154.1 ± 32.2	164.3 ± 30.4	0.17	155.8 ± 25.0	0.86
	LVEF	%	63.5 ± 5.8	65.1 ± 4.9	0.34	49.9 ± 5.0	<0.01
	RVEDV	mL	171.2 ± 36.0	181.6 ± 40.7	0.11	156.9 ± 33.1	<0.01
	RVEF	%	51.7 ± 3.5	53.3 ± 3.7	0.34	44.2 ± 5.1	<0.01
	LVM	g	86.9 ± 24.5	85.5 ± 24.6	0.52	81.1 ± 22.3	0.02
B
Non‐aCMP	T2	ms	52.0 ± 3.5	52.9 ± 2.7	0.07	54.6 ± 3.2	0.08
	Relative ECV	%	26.4 ± 2.0	28.1 ± 2.7	0.12	29.4 ± 1.6	0.06
	Absolute ECV	g	21.0 ± 5.4	23.4 ± 5.8	0.20	23.7 ± 3.9	0.08
aCMP	T2	ms	54.3 ± 2.8	55.3 ± 1.5	0.37	54.8 ± 2.9	0.73
	Relative ECV	%	27.5 ± 2.7	29.3 ± 2.7	0.16	29.8 ± 1.7	0.04
	Absolute ECV	g	23.4 ± 9.2	25.4 ± 8.6	0.33	26.8 ± 4.5	0.15

aCMP, anthracycline‐induced cardiomyopathy; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end‐diastolic volume; LVM, left ventricular mass; RVEF, left ventricular ejection fraction; RVEDV, right ventricular end‐diastolic volume.

P values indicate statistical significance towards baseline data (before therapy).